Home > Press > Livingston Securities “Healthcare Investment Series” Webinar Covers Emerging Models for Pharma Exits and Deals
Livingston Securities (www.livingstonsecurities.com) held their first of a series of webinars covering innovation and dealmaking trends in healthcare and life sciences on June 25, 2009. Participants in the Livingston Securities "627 Club" webinars gain important insights into investment and business opportunities in nanotechnology-focused companies across multiple sectors. Healthcare and Life Sciences have been of particular interest to investors in recent months, and these webinars will continue over the summer leading up to the 2nd annual Livingston Securities Healthcare Advanced and Nanotechnology Investor Summit on September 24, 2009 in New York City.
Livingston Securities “Healthcare Investment Series” Webinar Covers Emerging Models for Pharma Exits and Deals
New York, NY | Posted on July 7th, 2009
The Livingston Securities Healthcare Webinar featured panelists from venture capital, private equity, pharmaceutical executives, advisors to the Obama administration, startups and emerging public companies, all discussing the current status of healthcare and life science investments, along with emerging models for M&A and partnerships.
The webinar was chaired by Dr. Mostafa Analoui, Head of Healthcare & Life Sciences for the Livingston Group of Companies . Panelists included Dr. David Collier, Managing Director of CMEA Capital, Dr. Michael Nowak, Managing Director at Yorkville Advisors, Dr. Gil Omenn, Director of the Center for Computational Medicine & Biology at University of Michigan and former President of the American Association for the Advancement of Science, Dr. Michael Krams, Vice President of Wyeth, Dr. Eugene Seymour, CEO of NanoViricides and Mr. Rodney Brown, CEO of PharmaNova.
Key topics included the current state of VC funding for healthcare and life science companies, impact of the recent credit crunch and lack of IPOs on VC-backed companies, as well as future directions for creative financing and deal making. Private equity strategies for mergers and acquisitions were presented by a number of PE firms in healthcare. Other discussions included plans to achieve universal health care and the impact on cost and pricing, and the impact on venture investment in research & development, and innovative methods for design and execution of clinical trials. CEOs representing early stage public and private companies described their business strategies for financial viability and innovative models for collaborations and product development.
Livingston Securities will hold its 2nd webinar covering healthcare investment trends on Monday, July 27, 2009. For details please contact or visit our website at www.livingstonsecurities.com.
About Livingston Securities
Livingston Securities is dedicated to providing corporate finance and strategic advisory services to corporate clients and sales, trading and related services to institutional investors and high net worth individuals who focus on disruptive technologies and their impact on healthcare, energy, infrastructure and other leading sectors of the American and global economy. Our goal is to provide a unique perspective and expertise on investments in nanotechnology and in companies that are commercializing and/or impacted by scientific advances in the emerging field of nanotechnology.
For more information, please click here
For Livingston Securities
Steven Wright-Mark, 212-677-8700 ext. 29
Copyright © Business Wire 2009
If you have a comment, please Contact
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
FEI Company Announces Date for Investor Conference Participation March 3rd, 2014
Industrial Nanotech, Inc. Completes On Site Visit by PCAOB Audit Firm - Nears Completion of Audit in Preparation for Move to a Senior Stock Exchange in Late 2014 February 27th, 2014
Harris & Harris Group Announces the Consulting Engagement of Peter J. Boni as a Senior Advisor February 26th, 2014
Harris & Harris Group Notes Metabolon's Agreement With The Carlos Slim Institute, Patia And Clinica Ruiz For Quantose Prediabetes Test In Mexico February 25th, 2014
MANA Research Highlight: Smart nanofibers to treat kidney failure March 6th, 2014
Harris & Harris Group, Inc. Establishes and Invests $350,001 in ProMuc, Inc. March 6th, 2014
First Look at How Individual Staphylococcus Cells Adhere to Nanostructures Could Lead to New Ways to Thwart Infections: Berkeley Lab-led research could guide the development of bacteria-resistant materials March 5th, 2014
Dartmouth Researchers Find Promising Results with Local Hyperthermia of Tumors March 4th, 2014
Squeezing light into metals: University of Utah engineers control conductivity with inkjet printer March 7th, 2014
Up-Converted Radio: The way to treat radio waves in a noisy environment is to turn them into visible light March 7th, 2014
New Data Model Boosts Space Science March 6th, 2014
Carbodeon NanoDiamonds PTFE Coating doubles surface durability and reduces friction by up to 66 percent: New surface coating enables cost-effective CO2 and fuel reductions in machinery March 6th, 2014
Singapore's A*STAR IME will present 9 papers in optical device innovation and foundry-qualified platform development at world-class optical communications conference March 6th, 2014
How 19th Century Physics Could Change the Future of Nanotechnology: University of Cincinnati physics researchers have developed a new way of using an old technique that could help build better nanotechnology March 5th, 2014
Malvern Instruments announces guest presenter for March 18th protein characterization webinar: Renowned protein scientist Prof. Dr. John F. Carpenter shows how combining Dynamic Light Scattering with Raman Spectroscopy delivers new insights in protein stability, aggregation... March 4th, 2014
UC research tests which nano system works best in killing cancer cells: New UC research to be presented this week tested four iron-oxide nanoparticle systems to see which, when heated, would likely work best as a tool for targeting cancer cells March 4th, 2014